NovaBridge officer sells 107,978 shares at $0.74

NovaBridge Biosciences’ chief business development officer sold ADSs tied to RSU vesting to cover tax withholding, retaining a substantial direct shareholding.

Rhea-AI Filing Summary

NovaBridge Biosciences (NBP) reported that Chief Business Development Officer Cao Sean Wuxiong sold 107,978 Ordinary Shares on September 9, 2026, at a reported converted price of $0.74 per Ordinary Share, leaving him with 266,467 Ordinary Shares held directly.

The footnotes state that the transaction involved 46,947 American Depositary Shares (ADSs) representing approximately 107,978 Ordinary Shares, sold in connection with the partial vesting of a restricted stock unit award on September 3, 2026, solely to satisfy tax withholding obligations. The reported sales price corresponds to an ADS price of $1.6908. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 107,978 shares

Net Sell 1 txn

Insider Cao Sean Wuxiong

Role Chief Bus. Development Officer

Sold 107,978 shs ($80K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2, F3, F4	107,978	$0.74	$80K

Holdings After Transaction: Ordinary Shares — 266,467 shares (Direct)

Footnotes (4)

1. F1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
2. F2. The Reporting Person sold 46,947 ADSs representing approximately 107,978 ordinary shares in connection with the partial vesting of a restricted stock unit award on September 3, 2026, solely to satisfy tax withholding obligations incurred in connection with the vesting.
3. F3. Reported securities are represented by 46,947 ADSs.
4. F4. Reported sales price represents the converted sales price of the ADSs of $1.6908.

Key Figures

Ordinary Shares sold: 107,978 shares ADSs sold: 46,947 ADSs Price per Ordinary Share: $0.74 per share +3 more

6 metrics

Ordinary Shares sold 107,978 shares Sale on September 9, 2026 by Chief Business Development Officer

ADSs sold 46,947 ADSs ADSs representing the sold Ordinary Shares

Price per Ordinary Share $0.74 per share Converted from reported ADS sales price

Price per ADS $1.6908 per ADS Reported converted sales price of the ADSs

Shares held after transaction 266,467 Ordinary Shares Directly held by the insider following the sale

ADS to Ordinary Share ratio 10 ADSs represent 23 Ordinary Shares Representation ratio for NovaBridge Biosciences securities

Key Terms

American Depositary Shares, restricted stock unit, tax withholding obligations

3 terms

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares ("ADS")."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

restricted stock unit financial

"in connection with the partial vesting of a restricted stock unit award"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

tax withholding obligations financial

"solely to satisfy tax withholding obligations incurred in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NovaBridge Biosciences (NBP) disclose for Cao Sean Wuxiong?

NovaBridge Biosciences disclosed that Chief Business Development Officer Cao Sean Wuxiong sold 107,978 Ordinary Shares on September 9, 2026, represented by 46,947 ADSs, in connection with a partial vesting of a restricted stock unit award and related tax withholding.

What price was received in the NovaBridge Biosciences (NBP) insider sale?

The reported sales price represents a converted ADS price of $1.6908, corresponding to $0.74 per Ordinary Share. The filing states this as the converted sales price of the ADSs sold in the transaction.

How many NovaBridge Biosciences (NBP) shares does the insider hold after the transaction?

After the reported sale, Chief Business Development Officer Cao Sean Wuxiong directly holds 266,467 Ordinary Shares of NovaBridge Biosciences, according to the filing’s post-transaction ownership figure.

Why did the NovaBridge Biosciences (NBP) insider sell these ADSs and Ordinary Shares?

The filing states that the 46,947 ADSs, representing approximately 107,978 Ordinary Shares, were sold in connection with partial vesting of a restricted stock unit award and solely to satisfy tax withholding obligations from that vesting.

What is the ADS-to-Ordinary Share ratio mentioned for NovaBridge Biosciences (NBP)?

The filing explains that NovaBridge Biosciences’ Ordinary Shares may be represented by ADSs, where each 10 ADSs represent 23 Ordinary Shares of the issuer.

Was the NovaBridge Biosciences (NBP) insider sale under a Rule 10b5-1 trading plan?

No. The document-level Rule 10b5-1 checkbox is not marked as being under such a plan, and no footnote states that the sale was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 04:30 PM Accepted by SEC EDGAR 09/11/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cao Sean Wuxiong

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Bus. Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	09/09/2026		S(2)		107,978(3)	D	$0.74(4)	266,467	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. The Reporting Person sold 46,947 ADSs representing approximately 107,978 ordinary shares in connection with the partial vesting of a restricted stock unit award on September 3, 2026, solely to satisfy tax withholding obligations incurred in connection with the vesting.

3. Reported securities are represented by 46,947 ADSs.

4. Reported sales price represents the converted sales price of the ADSs of $1.6908.

	/s/ Kyler Lei, Attorney-in-Fact	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)